Pentax Medical renews ultrasound collaboration with Fujifilm

AuntMinnie.com staff writers
Jun 4, 2026

Pentax Medical has renewed its collaboration with Fujifilm for the supply of endoscopic ultrasound equipment, effective April 2026.

The renewed agreement covers Fujifilm's Arietta 850, Arietta 750, and Arietta 65 ultrasound scanners for use with Japan-based Pentax's EUS-J10 and EB-J10 echoendoscopes and Inspira video processor. The agreement includes product support for more than a decade.

FUJIFILM Healthcare Americas Corporation
Latest in Ultrasound
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Image-guided focal laser ablation effective for prostate cancer
June 3, 2026
Clarius 4 My3 Id27w X
Clarius gets FDA clearance for ejection fraction AI tool
June 2, 2026
Hepatus 6
Mindray launches Hepatus-Series ultrasound systems
June 2, 2026
Philips Epiq Elite
Philips gains FDA 510(k) clearance for Elevate Plus ultrasound AI
June 2, 2026
Related Stories
Fujifilm
Ultrasound
Fujifilm Sonosite launches AI tool for PIV procedures
Fujifilm
PACS/VNA
Fujifilm enters agreement with AWS
Fujifilm Rsna 2019 400
Enterprise Imaging
Fujifilm secures contract with Naval Medical Center in San Diego
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Interventional
Image-guided focal laser ablation effective for prostate cancer
More in Ultrasound
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Clarius gets FDA clearance for ejection fraction AI tool
By AuntMinnie.com staff writers
Calculates and displays LVEF percentage in real time.
June 2, 2026
Clarius 4 My3 Id27w X
Mindray launches Hepatus-Series ultrasound systems
By AuntMinnie.com staff writers
Mindray has launched its Hepatus-Series for ultrasound systems for gastroenterology imaging.
June 2, 2026
Hepatus 6
Philips gains FDA 510(k) clearance for Elevate Plus ultrasound AI
By AuntMinnie.com staff writers
Company highlights AI-powered workflow automation for Epiq Elite and Affiniti ultrasound systems.
June 2, 2026
Philips Epiq Elite
AIUM: Capacity building needed for global ultrasound initiatives
By Amerigo Allegretto
Ultrasound is useful in low-resource settings, but imagers in global health have some important considerations to make.
May 30, 2026
Img 6732
AIUM: Which ultrasound gel alternative is best?
By Amerigo Allegretto
KY Jelly, aloe vera, and glucomannan may be practical substitutes for commercial ultrasound gel in low-resource settings.
May 30, 2026
Keith Barron, MD, shares findings at AIUM 2026 on which ultrasound gel alternatives may be best for different environments in low-resource settings.
AIUM: Ultrasound-based AI model could help measure fetal lung maturity
By Amerigo Allegretto
An ultrasound-based AI model showed strong performance in assessing fetal lung maturity.
May 30, 2026
Nicole Adelson from Hofstra University presents findings at AIUM 2026 showing how an ultrasound-based AI model could help measure lung maturity in developing fetuses.
AIUM: To treat tumors, why not microbubbles?
By Amerigo Allegretto
A presentation given at AIUM 2026 outlined how microbubbles are a promising option for interventional procedures.
May 29, 2026
J. Brian Fowlkes, PhD, gives the William J. Fry Memorial Lecture at AIUM 2026, speaking on how microbubbles can help treat pathologies via histotripsy and acoustic droplet vaporization.
AIUM: Could AI help improve eFAST learning?
By Amerigo Allegretto
ChatGPT could assist novice learners training in eFAST exams, research presented at AIUM 2026 suggests.
May 29, 2026
Nardine Francis from the California University of Science and Medicine presents research at AIUM 2026 showing how ChatGPT could help novice learners in eFAST training.
AIUM: Ultrasound helps find nanoplastics in endometrial polyps
By Amerigo Allegretto
Research presented at AIUM shows how ultrasound helps measure nanoplastic retention in endometrial polyps.
May 29, 2026
Hailie Ciomperlik, MD, from Baylor University presents her team's results at AIUM 2026, showing how a multimodal approach featuring ultrasound shows nanoplastic retention within endometrial polyps.
Ultrasound MinnieCast, Episode 9: Training updates in CEUS
By Amerigo Allegretto
Maria Stanczak from ICUS shares her thoughts on recently proposed educational standards for CEUS training.
May 29, 2026
Minnie Cast Thumbnail (8)
AIUM: AI has evolving role in ultrasound
By Amerigo Allegretto
Dr. Alison Noble gave a keynote speech at AIUM 2026, showing ways that AI approaches are improving ultrasound scanning and workloads.
May 28, 2026
Alison Noble, PhD, from the University of Oxford shares work that she and colleagues have been working on toward AI in ultrasound at AIUM 2026.
Page 1 of 532
Next Page